RIGHT Checklist

Section/Topic	Item No	Item	Reported on Page Number/Line Number	Reported on Section/Paragraph
Basic information				
Title/subtitle	1a	Identify the report as a guideline, that is, with “guideline(s)” or “recommendation(s)” in the title.	Page1/Line2	Title
	1b	Describe the year of publication of the guideline.	Page1/Line2	Title
	1c	Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention, or others.	Page1/Line2	Title
Executive summary	2	Provide a summary of the recommendations contained in the guideline.	N/A*	N/A*
Abbreviations and acronyms	3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable.	Page13-14/Line279-295	Abbreviations and acronyms
Corresponding developer	4	Identify at least 1 corresponding developer or author who can be contacted about the guideline.	Page1-2/Line24-46	#Corresponding authors
Background				
Brief description of the health problem(s)	5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.	Page5/Line103-106	Background/prar1
Aim(s) of the guideline and specific objectives	6	Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.	Page5/Line106-109	Background/prar1
Target population(s)	7a	Describe the primary population(s) that is affected by the recommendation(s) in the guideline.	Page5/Line106-109	Background/prar1
	7b	Describe any subgroups that are given special consideration in the guideline.	Not applicable	Not applicable
End users and settings	8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policymakers) and other potential users of the guideline.	Page6/Line124-125	Method/prar3
	8b	Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities.	Page6/Line124-125	Method/prar3
Guideline development groups	9a	Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewers, systematic review team, and methodologists).	Page5/Line114-116	Method/para1
	9b	List all individuals involved in developing the guideline, including their title, role(s), and institutional affiliation(s).	Page1/Line8-21	Not applicable

Evidence				
Health care questions	10a	State the key questions that were the basis for the recommendations in PICO (population, intervention, comparator, and outcome) or other format as appropriate.	Page6/Line129-133	Method/para4
	10b	Indicate how the outcomes were selected and sorted.	Not applicable	Not applicable
Systematic reviews	11a	Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.	Page6/Line135-147	Method/para5
	11b	If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated.	Page6/Line135-147	Method/para5
Assessment of the certainty of the body of evidence	12	Describe the approach used to assess the certainty of the body of evidence.	Page8/Line149-157	Method/para6
Recommendations				
Recommendations	13a	Provide clear, precise, and actionable recommendations.	e11/Line233-234,242-245	Result/para2,5,8,11,14-17
	13b	Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.	Not applicable	Not applicable
	13c	Indicate the strength of recommendations and the certainty of the supporting evidence.	Not applicable	Not applicable
Rationale/explanation for recommendations	14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.	N/A†	N/A†
	14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.	Page8/Line160	Method/para7
	14c	Describe other factors taken into consideration when formulating the recommendations, such as equity, feasibility, and acceptability.	Page8/Line160-161	Method/para7
Evidence to decision processes	15	Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).	Page9/Line162-164	Method/para7

Review and quality assurance				
External review	16	Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.	Page9/Line164-166	Method/para7
Quality assurance	17	Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.	N/A‡	N/A‡
Funding and declaration and management of interests				
Funding source(s) and role(s) of the funder	18a	Describe the specific sources of funding for all stages of guideline development.	Page14/Line298	Funding/prar1
	18b	Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.	Not applicable	Not applicable
Declaration and management of interests	19a	Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.	Page14/Line299-300	Conflicts of interest/para1
	19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.	Not applicable	Not applicable
Other information				
Access	20	Describe where the guideline, its appendices, and other related documents can be accessed.	N/A§	N/A§
Suggestions for further research	21	Describe the gaps in the evidence and/or provide suggestions for future research.	Page12/Line268-272	Limitations/para1
Limitations of the guideline	22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations.	Page12/Line268-272	Limitations/para1

RIGHT = Reporting Items for practice Guidelines in HealThcare.

Article information: https://dx.doi.org/10.21037/atm-20-7502
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

*The recommendations contained in this guideline have already be presented by separate items, thus we do not provide the summary of it.
†This guideline is focus on the prescription comment, therefore we have no need to investigate the values and preference.
‡The guideline will be sent to the Pharmaceutical Affairs Commission of the Chinese Hospital Association for quality control.
§.When the guideline accepted, people can scan it and other related documents online.